ELL

RNA polymerase II elongation factor ELL · P55199 · ELL on Sugi Atlas →

0 patent compounds predicted against ELL, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to ELL by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer PHASE2COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer PHASE1/PHASE2COMPLETED
A Prevention Trial in Subjects at High Risk for Breast Cancer PHASE2COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC PHASE2COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Tamoxifen in Patients With Oesophageal Cancer PHASE1UNKNOWN
Broccoli Sprout Extract in Treating Patients With Breast Cancer EARLY_PHASE1COMPLETED
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors nanCOMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Esophageal String Test in Eosinophilic Esophagitis nanACTIVE_NOT_RECRUITING
miR-155 Expression in Episodic and Chronic Migraine nanUNKNOWN
Spironolactone and XPB-1 Integrity in the TFIIH Complex nanENROLLING_BY_INVITATION
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
Markers for Predicting Risk of Breast Cancer in Women of Different Races nanWITHDRAWN
Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene Mutations in Acromegaly nanUNKNOWN
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN
Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus nanACTIVE_NOT_RECRUITING
Quantification of GADD34 Expression in RA nanCOMPLETED
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults nanCOMPLETED
Effect of Branched Chain Amino Acids on Muscle nanCOMPLETED
Can COVID-19 Persist in Intraocular Fluid? nanCOMPLETED
Assessment Of Long Noncoding RNA CCAT1 In Colorectal Cancer Patients nanUNKNOWN
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a ELL binder may also engage these)

ProteinNameSimilarity
O08856 0.992 O08856 →
Q3UKU1 0.984 Q3UKU1 →
Q8TBN0 0.976 Q8TBN0 →
Q66T02 0.975 Q66T02 →
Q9Y2B5 0.974 Q9Y2B5 →
P49797 0.974 P49797 →
Q69Z89 0.974 Q69Z89 →
Q9BUN5 0.973 Q9BUN5 →
Q4R4I0 0.972 Q4R4I0 →
P12755 0.972 P12755 →
Q8C190 0.972 Q8C190 →
A4D2P6 0.972 A4D2P6 →
Q2KJ58 0.971 Q2KJ58 →
O00472 0.971 O00472 →
Q8N228 0.971 Q8N228 →
Q86UK7 0.971 Q86UK7 →
Q9TUG2 0.971 Q9TUG2 →
Q9DD19 0.971 Q9DD19 →
O77638 0.971 O77638 →
Q8VDV3 0.970 Q8VDV3 →
TERF2IP Telomeric repeat-binding factor 2-interacting protein 1 0.970 landscape →
Q9DC04 0.970 Q9DC04 →
Q3UR85 0.970 Q3UR85 →
Q5SNT2 0.970 Q5SNT2 →
Q96JH8 0.969 Q96JH8 →
Q8CEG5 0.969 Q8CEG5 →
NFATC1 Nuclear factor of activated T-cells, cytoplasmic 1 0.968 landscape →
Q80YR4 0.968 Q80YR4 →
PML Protein PML 0.967 landscape →
MBD2 Methyl-CpG-binding domain protein 2 0.967 landscape →